JAK2 Antibody, FITC conjugated

Datasheet
Code CSB-PA011931LC01HU
Size US$299
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Full Product Name Rabbit anti-Homo sapiens (Human) JAK2 Polyclonal antibody
Uniprot No. O60674
Target Names JAK2
Alternative Names JAK 2 antibody; JAK-2 antibody; JAK2 antibody; JAK2_HUMAN antibody; Janus Activating Kinase 2 antibody; Janus kinase 2 (a protein tyrosine kinase) antibody; Janus kinase 2 antibody; JTK 10 antibody; JTK10 antibody; kinase Jak2 antibody; OTTHUMP00000043260 antibody; THCYT3 antibody; Tyrosine protein kinase JAK2 antibody; Tyrosine-protein kinase JAK2 antibody
Raised in Rabbit
Species Reactivity Human
Immunogen Recombinant Human Tyrosine-protein kinase JAK2 protein (752-1132AA)
Immunogen Species Homo sapiens (Human)
Conjugate FITC
Clonality Polyclonal
Isotype IgG
Purification Method >95%, Protein G purified
Concentration It differs from different batches. Please contact us to confirm it.
Buffer Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
Form Liquid
Tested Applications ELISA
Protocols ELISA Protocol
Troubleshooting and FAQs Antibody FAQs
Storage Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Target Data

Function Non-receptor tyrosine kinase involved in various processes such as cell growth, development, differentiation or histone modifications. Mediates essential signaling events in both innate and adaptive immunity. In the cytoplasm, plays a pivotal role in signal transduction via its association with type I receptors such as growth hormone (GHR), prolactin (PRLR), leptin (LEPR), erythropoietin (EPOR), thrombopoietin (THPO); or type II receptors including IFN-alpha, IFN-beta, IFN-gamma and multiple interleukins
Gene References into Functions
  1. Clonal analysis shows that the dominant JAK2 V617F-positive clone in Polycythemia Vera harbors EGFR C329R substitution, thus this mutation may contribute to clonal expansion. PMID: 28550306
  2. Patients with CALR mutation had significantly higher concentration of PDGF-BB and lower concentration of SDF-1alpha than patients with JAK2V617F mutation. High concentration of PDGF-BB and low concentration of SDF-1alpha in patients with CALR(+) ET may indicate a contribution of these chemokines in disturbed Ca2+ metabolism in platelets. PMID: 29390868
  3. Here, we present two crystal structures of the human JAK2 FERM and SH2 domains bound to Leptin receptor (LEPR) and Erythropoietin receptor (EPOR), which identify a novel dimeric conformation for JAK2. PMID: 30044226
  4. pathogenesis mechanism of JAK2 F556V mutation in the MPNs PMID: 29842959
  5. Mir-204 attenuates angiogenesis in lung adenocarcinoma via JAK2-STAT3 pathway. PMID: 29281186
  6. FEZF1-AS1 acts as an oncogenic lncRNA in human hepatocellular carcinoma by promoting JAK2/STAT3 signaling-mediated epithelial mesenchymal transformation. PMID: 29957463
  7. Case Reports/Review: JAK2 mutation-associated cerebral arterial infarction and cerebral and systemic venous thromboembolism. PMID: 30056970
  8. HSP27 is a partner of JAK2-STAT5 and a potential therapeutic target in myelofibrosis. PMID: 29650953
  9. Our study suggests that JAK2V617F mutation may increase the risk of thrombosis in chronic myeloproliferative neoplasms. PMID: 30004057
  10. Progression to polythythemia vera from familial thrombocytosis with germline JAK2 R867Q mutation. PMID: 29368262
  11. JAK2 and STAT3 are activated in Idiopathic pulmonary fibrosis PMID: 29409529
  12. The prevalence of CALR mutation in JAK2V617F-negative essential thrombocythemia in this study is 35.7%. HRM is an effective method of detecting CALR mutation and is a more advantageous method of screening for CALR mutation. PMID: 29521158
  13. Comprehensive genomic characterization identified distinct genetic subgroups and provided a classification of myeloproliferative neoplasms on the basis of causal biologic mechanisms. Mutations in JAK2, CALR, or MPL being the sole abnormality in 45% of the patients. PMID: 30304655
  14. Findings outlined in the current study demonstrated that the inhibition of P16 decreased the growth and metastasis potential of BC cells by inhibiting IL-6/JAK2/STAT3 signaling. PMID: 29388151
  15. MPL-mutated and CALR-mutated essential thrombocythaemia share clinical and histological characteristics, with both genotypes showing higher platelet counts and a marked megakaryocytic proliferation in comparison with JAK2V617F-mutated ET. PMID: 29934356
  16. results herein provide clues to understand the mechanism JAK2 V625F mutation caused myeloproliferative neoplasms and give information for the development of JAK2 mutation specific inhibitors. PMID: 29782975
  17. Concomitant presence of JAK2V617F mutation and BCRABL translocation in two patients: A new entity or a variant of myeloproliferative neoplasms. PMID: 29845291
  18. The JAK2 V617F mutation and thrombocytopenia. PMID: 27614229
  19. PBX1 plays an oncogenic role in clear cell renal carcinoma via JAK2/STAT3 pathway PMID: 29678569
  20. Our study shows that JAK2V617F leads to abnormal expression of numerous proteins at the membrane of circulating PV red blood cells, with overexpression of CALR and persistence of CANX PMID: 28385780
  21. In 94.9% of PV, 85.5% ET and 85.2% PMF, authors found mutations in JAK2, MPL or CALR. 74.9% carried JAK2V617F, 12.3% CALR mutations, 2.1% MPL mutations and 10.7% were triple negative. PMID: 28990497
  22. tyrphostin B42 induced the apoptosis of pancreatic cancer cells (PCCs) by regulating the expression of mitochondrialrelated genes. Therefore, these findings demonstrated that tyrphostin B42 attenuated trichostatin A resistance in PCCs by antagonizing the IL6/JAK2/STAT3 signaling PMID: 29393444
  23. MiR-375 inhibits fetal ASM cell proliferation and migration by targeting JAK2/STAT3 signaling. PMID: 29245068
  24. data show that HIT is more frequent, during heparin treatment, in patients with ET carrying V617F mutation, as compared with patients without mutations PMID: 29022213
  25. Overexpression of ALK4 suppressed glioma cell proliferation, migration and invasion through the inactivation of JAK/STAT3 signaling pathway. PMID: 29278854
  26. We describe a subset of non-small-cell lung cancer patients who had JAK2 amplifications resulting in high expression of PD-L1 PMID: 28795418
  27. High JAK2 expression is associated with hepatocellular carcinoma. PMID: 28677802
  28. JAK2 haplotype 46/1 and JAK2 V617F allele burden in MPN PMID: 29134760
  29. Low JAK2 expression is associated with gastric cancer. PMID: 28656307
  30. The authors discovered tyrosine 78 of Atoh1 is phosphorylated by a Jak2-mediated pathway only in tumor-initiating cells and in human Sonic Hedgehog-type medulloblastoma. PMID: 29168692
  31. conclude that the activating JAK2 V617F mutation does not play a decisive role in the pathogenesis of progressive CKD PMID: 27889755
  32. Our findings revealed that B7-H3 affect ovarian cancer progression through the Jak2/Stat3 pathway, indicating that B7-H3 has the potential to be a useful prognostic marker. PMID: 28765941
  33. In 136 patients with myelofibrosis and a median age of 58 years who underwent allogeneic stem cell transplantation (AHSCT) for molecular residual disease, the percentage of molecular clearance on day 100 was higher in CALR-mutated patients (92%) in comparison with MPL- (75%) and JAKV617F-mutated patients (67%). PMID: 28714945
  34. Mutational subtypes of JAK2 correlate with different clinical features in Japanese patients with myeloproliferative neoplasms. PMID: 29464483
  35. identification of activating somatic mutations in JAK2 and germline mutations in JAK3 with clinical implications PMID: 29082853
  36. Screening for the JAK2 V617F mutation in cerebral venous thrombosis patients seems to be useful because of its relatively high prevalence and the risk of thrombosis recurrence. PMID: 28609766
  37. Ascochlorin significantly decreased phosphorylation of JAK2/STAT3, cancer cell migration and nuclear translocation of STAT3. PMID: 28569433
  38. TLR7, TLR9, and JAK2 genes are potential biomarkers for systemic sclerosis. High TLR7 expression positively correlated with the late form of disease. Decreased levels of TLR9 and JAK2 mRNA were found in the patient's cohort in comparison to non-SSc individuals. PMID: 29147913
  39. This study demonstrated that the JAK2V617F mutation was detectable in Patients with Stroke. PMID: 28625126
  40. Curcumin attenuated neuropathic pain and down-regulated the production of spinal mature IL-1beta by inhibiting the aggregation of NALP1 inflammasome and the activation of the JAK2-STAT3 cascade in astrocytes. PMID: 27381056
  41. High level of phosphorylated JAK2, and STAT3 are associated with systemic lupus erythematosus. PMID: 28177455
  42. this study shows that Nrf2 activation induces lipocyte phenotype in hepatic stellate cells via enhancing SOCS3-dependent feedback inhibition on JAK2/STAT3 cascade PMID: 28601022
  43. bladder cancer cell may inhibit maturation and function of dendritic cells involving of Jak2/STAT3 pathway, and there may be different mechanisms by which adriamycin-resistant BCC restrains DC function in antitumor immune response PMID: 27556503
  44. Multivariate analysis adjusted for age, sex, follow-up period and hematological parameters confirmed that increased activated B cells were universally present in JAK2-mutated, CALR-mutated and triple-negative ET patients when compared to healthy adults. PMID: 28415571
  45. In multivariable analysis, younger age, platelet count, hemoglobin level and JAK2 V617F mutation independently predicted the development of acquired von Willebrand syndrome (AVWS) among essential thrombocythemia (ET)patients; whereas only platelet count predicted its development among polycythemia vera (PV) patients. Among ET patients, JAK2 V617F was a main driver for the development of AVWS. PMID: 27919526
  46. CXCR4 induced VEGF production and JAK2/STAT3 activation and enhanced STAT3 binding to VEGF promoter in gastric cancer cells. PMID: 28544312
  47. these results reveal proteome alterations in MPN granulocytes depending on the phenotype and genotype of patients, highlighting new oncogenic mechanisms associated with JAK2 mutations and overexpression of calreticulin PMID: 28314843
  48. JAK2 mutation is associated with Essential thrombocythemia. PMID: 28205126
  49. Considering JAK2(V617F) -positive disease, a higher (>50%) JAK2(V617F) burden and histological classification are independent prognostic risk factors for disease progression. PMID: 28509339
  50. Taken together, we found that silibinin inhibits the Jak2/STAT3/MMP2 signaling pathway, and inhibits the proliferation, migration, and invasion of triple-negative breast cancer cells. PMID: 28440514
  51. in molecularly annotated ET patients at diagnosis, JAK2-V617F patients have more circulating microparticles and higher MP-associated procoagulant activities than CALR-mutated and TN ET patients. PMID: 27247323
  52. We report a novel somatic mutation in JAK2 exon 14, and show that sequencing of exon 14 can identify a small proportion of PV-associated mutations that would be missed by most diagnostic laboratories. PMID: 27136492
  53. we have identified JAK2V617F mutations in JAK2V617F BM E-CFC from JAK2V617F MPN-neg patients with BCS. We have also demonstrated the absence of recurrent myeloid-associated mutations and a low JAK2V617F VAF in the granulocytes of these patients. PMID: 27650062
  54. The co-occurrence of JAK2 V617F and BCR-ABL1 clones in the same patient is a rare event. PMID: 26847954
  55. JAK2 and CALR mutations have roles in patients with essential thrombocythemia PMID: 27486987
  56. onstitutive Gab1-dependent signalling in Jak2-V617F-expressing cells does not occur due to the constitutive association of Gab1 with PIP3 at the plasma membrane. PMID: 28365441
  57. The results suggested that HGF may inhibit TEMT by inhibiting AngII through the JAK2/STAT3 signaling pathway in HK2 cells and HGF may prevent apoptosis induced by AngII. The present study provides a basis for understanding the mechanisms involved in the inhibition of TEMT by HGF, which requires further investigation PMID: 28447719
  58. Clinical features of JAK2V617F- or CALR-mutated essential thrombocythemia and primary myelofibrosis. PMID: 26994960
  59. NGS may be useful to identify a minority of Polycythemia vera and essential thrombocythemia patients with high genetic instability and increased risk of acute myeloid leukemia transformation. PMID: 29181548
  60. IL-10 from M2 macrophage promoted proliferation of glioma through interaction with JAK2. PMID: 27765933
  61. JAK2 germline mutations coexist with JAK2V617F in Polycythemia vera. PMID: 27647865
  62. Food intake had minimal impact on the pharmacokinetics of JAK2 inhibitor fedratinib. The tolerability of this drug was improved when taken following a high-fat breakfast. PMID: 27136912
  63. The JAK2 V617F and non-V617F mutations have a diagnostic sensitivity of 98% to 100% for Polycythemia Vera. This means that the presence of a JAK2 mutation can be used as a clonal marker to distinguish Polycythemia Vera from reactive secondary causes of Erythrocytosis. PMID: 27618352
  64. STIP1 modulates the function of the HSP90-JAK2-STAT3 complex PMID: 27409672
  65. Decreased expression of JNK2 in T24 cells conferred resistance to cell death induced by mitomycin C PMID: 27147566
  66. JAK2(V617F) mutation is associated with myelofibrosis. PMID: 29101828
  67. the frequencies of mutations from JAK2 wild-type to JAK2V617F and vice versa increased following erythroid differentiation PMID: 28126623
  68. we report that the recipient and the donor JAK2 46/1 haplotypes are significantly associated with aGvHD grades II-IV in AML patients undergoing allo-HSCT. PMID: 27389386
  69. our studies suggest that the JAK2(V617F)-bearing ECs form an important component of the myeloproliferative neoplasms vascular niche and contribute to mutant stem/progenitor cell expansion, likely through a critical role of the TPO/MPL signaling axis. PMID: 27865175
  70. Data show that co-treated with vincristine and XL019, a inhibitor of JAK2 and P-glycoprotein (P-gp), up-regulated expression of p21 and phosphorylated H2A histone family, member X (pH2AX). PMID: 29187454
  71. dehydrocostus lactone significantly inhibits the phosphorylation expression of Bcr/Abl, STAT5, JAK2, and STAT3 and downstream molecules including p-CrkL, Mcl-1, Bcl-XL, and Bcl-2 proteins in K562 cells. PMID: 28300289
  72. JAK2V617F mutation influences myeloproliferative neoplasm-associated inflammation with a strong correlation between allele burden and PTX3 levels. PMID: 28228104
  73. TGR5 exhibits significantly higher expression in NSCLC tumor samples and facilitates the growth and metastasis of NSCLC by activating the JAK2/STAT3 signaling pathway. PMID: 29074425
  74. JAK2V617F mutations were found in 59 patients in the olycythemia vera group PMID: 28164603
  75. Essential Thrombocythemia and Primary Myelofibrosis patients with JAK2 V617F mutations are at high risk for Thrombotic Events. PMID: 28766534
  76. CIS interacted with phosphorylated EpoR at Y401, which was critical for the activation of STAT5 and ERK. PMID: 28038963
  77. Therefore, JAK2V617F influences target binding in both pSTAT3 and EZH2. Without mutations in epigenetic regulators, JAK2V617F can induce downstream epigenomic modifications. Thus, epigenetic changes in JAK2 downstream targets might be trackable in vivo. PMID: 29066347
  78. the immune system is able to effectively target cancer cells carrying the JAK2V617F mutation PMID: 27761006
  79. Subjects with JAK2V617F mutation and an allele burden>/=50% had an age-independent higher incidence of elevated hs-CRP level (OR=1.97; 95% CI,1.21-3.22; P=0.006) compared with a combined cohort of subjects with JAK2V617F <50% allele burden PMID: 28622624
  80. High JAK2 expression is associated with neuroblastoma. PMID: 28687621
  81. Single-nucleotide polymorphism in JAK2 gene is associated with breast cancers. PMID: 28775167
  82. When transduced into rad chimera mice, 3 human activating JAK2 mutants can differentially couple to selective cytokine receptors EpoR and GCSFR and change the signaling repertoire, revealing the molecular basis for phenotypic differences elicited by JAK2 (V617F) or mutations in exon 12. PMID: 28057939
  83. inhibition of the H3K27 demethylase JMJD3 in naive CD4 T cells demonstrates how critically important molecules required for T cell differentiation, such as JAK2 and IL12RB2, are regulated by H3K27me3. PMID: 28947543
  84. Testing for JAK2 mutations is now included in the World Health Organization (WHO) criteria for the diagnosis of MPN, and in 2011 the oral JAK2 kinase inhibitor ruxolitinib became the first Food and Drug Administration (FDA)-approved drug for the treatment of myelofibrosis. PMID: 27796499
  85. In our study, there was no genotypic or phenotypic association between the JAK2 rs10758669 variant and UC. Only the (C) allele was identified to increase the risk of a more severe disease progression. PMID: 27852544
  86. C-CALR in response to Ca2+ undergoes conformational changes that trigger its function to export GR from the nucleus, resetting the stress response of normal erythroid cells. Impairment of this function in JAK2V617F-positive erythroid cells maintains EPO-R signaling in proliferation mode, contributing to erythrocytosis in PV. PMID: 28232234
  87. BRM could activate JAK2/STAT3 pathway to promote pancreatic cancer growth and chemoresistance. PMID: 28602977
  88. Regulation of platelet-activating factor-mediated PTP1B activation by a Janus kinase 2/ calpain pathway has been reported. PMID: 28686728
  89. Molecular interactions of EphA4, growth hormone receptor, Jak2, and STAT5B have been described. PMID: 28686668
  90. Peritoneal membrane dysfunction in long-term peritoneal dialysis patients may result from IL-6 promotion of epithelial-to-mesenchymal transition of human peritoneal mesothelial cells possibly through the JAK2/STAT3 signaling pathway. PMID: 28490530
  91. Mutation inactivating JAK2 gene is associated with Breast Cancer Metastasis. PMID: 28810143
  92. mechanical load upregulates expression of Runx2 gene via potentiation of PC1-JAK2/STAT3 signaling axis, culminating to possibly control osteoblastic differentiation and ultimately bone formation. PMID: 27699453
  93. blocking the ERRalpha-controlled mitochondrial program largely inhibits the PLA2R1-induced tumor-suppressive response. Together, our data document ERRalpha and its mitochondrial program as downstream effectors of the PLA2R1-JAK2 pathway leading to oncosuppression. PMID: 27041564
  94. TP53mut and JAK2mut are potential biomarkers associated with poor prognosis in B-cell precursor acute lymphoblastic leukaemia (B-ALL) patients PMID: 28557976
  95. JAK2 was overexpressed in Epstein Barr virus-associated gastric adenocarcinoma. PMID: 26980034
  96. As marrow histology in this murine model of myeloproliferation reveals a preferentially perivascular localization of JAK2(V617F)-mutant megakaryocytes and an increased marrow sinusoid vascular density PMID: 27133820
  97. mutated FLT3-ITD and JAK2 augment reactive oxygen species production and homologous recombination, shifting the cellular milieu toward illegitimate recombination events. PMID: 28108507
  98. Germ line JAK2 mutations E846D and R1063H are associated with hereditary erythrocytosis with megakaryocytic atypia. PMID: 27389715
  99. Data suggest that ruxolitinib treatment for up to 4 years provides progressive reductions in Janus kinase 2 (JAK2) p.V617F allele burden in patients with polycythemia vera (PV). PMID: 28456851
  100. Mice expressing the human JAK2-N542-E543del (Ex12) showed a strong increase in red blood cell parameters but normal neutrophil and platelet counts, and reduced overall survival. Erythropoiesis was increased in the bone marrow and spleen, with normal megakaryopoiesis and absence of myelofibrosis in histopathology. PMID: 27288519

Show More

Hide All

Involvement in disease Budd-Chiari syndrome (BDCHS); Polycythemia vera (PV); Thrombocythemia 3 (THCYT3); Myelofibrosis (MYELOF); Leukemia, acute myelogenous (AML)
Subcellular Location Endomembrane system, Peripheral membrane protein, Cytoplasm, Nucleus
Protein Families Protein kinase superfamily, Tyr protein kinase family, JAK subfamily
Tissue Specificity Ubiquitously expressed throughout most tissues.
Database Links

HGNC: 6192

OMIM: 147796

KEGG: hsa:3717

STRING: 9606.ENSP00000371067

UniGene: Hs.656213

Most popular with customers

  Tel: 301-363-4651
  Email: support@cusabio.com
  Distributors Worldwide

Newsletters

Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

Copyright © 2007-2018 www.cusabio.com CUSABIO TECHNOLOGY LLC All Rights Reserved. 鄂ICP备15011166号-1